Sugi Predict

Sugi Predict / Compounds / SCHEMBL1345783

SCHEMBL1345783

SCHEMBL1345783

CCCc1ccc(-c2nnn(CC(C)(C)C(=O)NCCc3ccccc3Cl)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.44
▸ TP53 P04637 3/20 0.44
▸ MAPT P10636 3/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ RAB9A P51151 3/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ ATM Q13315 1/20 0.42
▸ POLB P06746 2/20 0.42
▸ USP2 O75604 1/20 0.42
▸ HIF1A Q16665 1/20 0.41
▸ LMNA P02545 2/20 0.41
▸ NPC1 O15118 2/20 0.40
▸ CASP3 P42574 1/20 0.40
▸ SENP8 Q96LD8 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ GPR139 Q6DWJ6 1/20 0.40
▸ RIPK1 Q13546 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1344382 0.93 MAPT (0.46) THRBTP53MAPTMEN1KMT2A
SCHEMBL1345781 0.88 TP53 (0.47) THRBTP53MAPTMEN1KMT2A
SCHEMBL1345924 0.87 THRB (0.39) THRBTP53MAPTMEN1KMT2A
SCHEMBL1346103 0.85 MAPT (0.49) THRBTP53MAPTMEN1KMT2A
SCHEMBL1345983 0.84 LMNA (0.50) THRBTP53MAPTMEN1KMT2A
SCHEMBL1346807 0.83 SMN1; SMN2 (0.51) THRBTP53MEN1KMT2ASMN1; SMN2
SCHEMBL1346178 0.83 RIPK1 (0.52) THRBTP53MAPTMEN1KMT2A
SCHEMBL1345985 0.83 MAPT (0.47) THRBTP53MAPTMEN1KMT2A
SCHEMBL1345742 0.83 MEN1 (0.50) THRBTP53MAPTMEN1KMT2A
SCHEMBL1346801 0.81 LMNA (0.44) TP53MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063082-B2 E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-11-22 — — US claimed
US-20080132548-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 — — US claimed
US-8063082-B2 E.g., N-[(2-chlorophenyl)methyl]({[5-(4-ethylphenyl)(1,2,3,4-tetraazol-2-yl)]methyl}cyclopropyl)carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-11-22 — — US disclosed
US-20080132548-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132548-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 THRB 2371/4885TP53 2206/4885MAPT 530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.